Kyntra Bio develops cancer and anemia treatments, including a prostate cancer drug candidate and roxadustat, from San Francisco. It last closed at $2.05 on Nov 17, down 33.87% on the day. The average 12-month price target from 4 analysts is $22.75 (+1009.8% from the last close), with a high of $35.00 and a low of $8.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Each firm's latest rating on KYNB in the past 90 days
Average 12-month target
$22.75
▲ 1009.8% upside
Based on 4 analysts who set a price target on KYNB in the past 90 days. The average target is $22.75, with a high of $35.00 and a low of $8.00, compared with the last close of $2.05.
Low $8.00Avg $22.75High $35.00
Blue marker: last close $2.05
Highest target$35.00
Average target$22.75
Lowest target$8.00
Latest rating changes
Lake StreetTarget lowered
Nov 17Buy$41 → $8
OppenheimerTarget lowered
Nov 17Buy$35 → $30
HC Wainwright & Co.Target lowered
Nov 17Buy$43 → $18
Maxim GroupInitiated
Oct 13Buy$35
Lake StreetInitiated
Sep 17Buy$41
Date
Firm
Action
Rating
Price target
Nov 17
Lake Street
Target lowered
Buy
$41 → $8
Nov 17
Oppenheimer
Target lowered
Buy
$35 → $30
Nov 17
HC Wainwright & Co.
Target lowered
Buy
$43 → $18
Oct 13
Maxim Group
Initiated
Buy
$35
Sep 17
Lake Street
Initiated
Buy
$41
Loading…
Technical Analysis
KYNB · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 99% below its 20 day and 174% below its 50 day average. It is 232% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 14), oversold. The nearest support is the 52 week low at $2.00, and the nearest resistance the Pivot at $2.10.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 19.1%/day
Key levels
$10.4752 week high+410.7%
$6.80200 day average+231.7%
$6.50100 day average+217.1%
$5.6150 day average+173.7%
$4.85Swing high (Oct 29)+136.6%
$4.0720 day average+98.5%
$2.19Pivot R1+6.8%
$2.10Pivot+2.4%
$2.05Last close
$2.0052 week low−2.4%
$1.95Pivot S1−4.9%
Indicators
RSI (14)
14.15
Oversold below 30
Oversold
MACD
-0.76
Below its signal line
Bearish
Stochastic
2.0
Near the bottom of its range
Oversold
ADX (14)
62.2
Strong downtrend
Williams %R
-98.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-233.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−52.4%
Change over 10 sessions
Bearish
ATR (14)
$0.39
Typical daily range, 19.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 43.0%/day
Key levels
$10.4752 week high+410.7%
$6.80200 day average+231.7%
$6.50100 day average+217.1%
$5.6150 day average+173.7%
$4.85Swing high (Oct 29)+136.6%
$4.0720 day average+98.5%
$2.19Pivot R1+6.8%
$2.10Pivot+2.4%
$2.05Last close
$2.0052 week low−2.4%
$1.95Pivot S1−4.9%
Indicators
RSI (14)
19.67
Oversold below 30
Oversold
MACD
-1.09
Below its signal line
Bearish
Stochastic
1.6
Near the bottom of its range
Oversold
ADX (14)
26.3
Trending down
Williams %R
-99.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-193.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−74.3%
Change over 10 sessions
Bearish
ATR (14)
$0.88
Typical daily range, 43.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KYNB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KYNB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow KYNB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KYNB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYNB is in one of them and how their past KYNB trades turned out.
Kyntra Bio is a biopharmaceutical company in San Francisco, California, that develops treatments for cancer and anemia. Its lead program, FG-3246, is a drug candidate for advanced prostate cancer, paired with FG-3180, an imaging agent that helps identify suitable patients. The company also holds rights to roxadustat, a treatment for anemia in patients with chronic kidney disease, and is developing it for a blood disorder called myelodysplastic syndromes.